Supplemental material
Human Vaccines & Immunotherapeutics
Volume 10, 2014 - Issue 8
Related Research Data
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
Source:
Elsevier BV
Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications
Source:
Springer Science and Business Media LLC
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
Source:
Elsevier BV
Will HPV vaccination prevent cervical cancer
Source:
SAGE Publications
Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.
Source:
(:unav)
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives
Source:
Elsevier BV
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
Source:
Informa UK Limited
HPV-associated cancers
Source:
Springer Science and Business Media LLC
Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age.
Source:
Charité - Universitätsmedizin Berlin
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Source:
Ovid Technologies (Wolters Kluwer Health)
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
Source:
Elsevier BV
Safety of Human Papillomavirus Vaccines: An Updated Review.
Source:
Springer Science and Business Media LLC
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Source:
American Association for Cancer Research (AACR)
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women
Source:
Elsevier BV
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
Source:
Informa UK Limited
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases
Source:
Informa UK Limited
Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
Source:
Massachusetts Medical Society
Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Source:
Oxford University Press (OUP)
Primary Prevention of HPV through Vaccination: Update on the Current Global Status
Source:
Springer Science and Business Media LLC
Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women.
Source:
Elsevier BV
An investigation into the role of chronic Schistosoma mansoni infection on Human Papillomavirus (HPV) vaccine induced protective responses
Source:
Public Library of Science (PLoS)
Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females
Source:
Public Library of Science (PLoS)
Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine
Source:
Elsevier BV
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Source:
Elsevier BV
Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer
Source:
Oxford University Press (OUP)
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Source:
Elsevier BV
Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
Source:
Elsevier BV
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.
Source:
Informa UK Limited
Linking provided by
